| Dr Tyler John Ulbrich, MD | |
|
640 Jackson St, Saint Paul, MN 55101-2502 | |
| (651) 254-3456 | |
| (651) 254-9673 |
| Full Name | Dr Tyler John Ulbrich |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 11 Years |
| Location | 640 Jackson St, Saint Paul, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801139795 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 58859 (Minnesota) | Secondary |
| 208M00000X | Hospitalist | 65475-20 (Wisconsin) | Secondary |
| 207R00000X | Internal Medicine | 58859 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Regions Hospital | Saint paul, MN | Hospital |
| Hudson Hospital | Hudson, WI | Hospital |
| Westfields Hospital And Clinic | New richmond, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hutchinson Health | 0345330072 | 122 |
| Healthpartners Medical Group | 1759293954 | 1430 |
| Healthpartners Rc | 5890126726 | 34 |
| Hudson Hospital Inc | 0648183061 | 22 |
| Westfields Hospital Inc | 2264490960 | 52 |
| Amery Regional Medical Center Inc | 2769391960 | 97 |
| St. Croix Regional Medical Center | 9335032184 | 164 |
News Archive
Over 65s say they would find technology to help them take their medications helpful, but need the technology to be familiar, accessible and easy to use, according to research by Queen Mary University of London and University of Cambridge.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
A political drive, led by the UK and US, to screen older people for minor memory changes (often called mild cognitive impairment or pre-dementia) is leading to unnecessary investigation and potentially harmful treatment for what is arguably an inevitable consequence of ageing, warn University of Sydney experts in in a paper published in the British Medical Journal today.
ERADA Technology Alliance Ltd, pioneers of innovative, rapid diagnostic solutions for early detection of infectious diseases, have announced the imminent launch of a world first diagnostic saliva test for malaria.
› Verified 9 days ago
| Entity Name | Park Nicollet Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780621904 PECOS PAC ID: 7911819438 Enrollment ID: O20031104000046 |
News Archive
Over 65s say they would find technology to help them take their medications helpful, but need the technology to be familiar, accessible and easy to use, according to research by Queen Mary University of London and University of Cambridge.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
A political drive, led by the UK and US, to screen older people for minor memory changes (often called mild cognitive impairment or pre-dementia) is leading to unnecessary investigation and potentially harmful treatment for what is arguably an inevitable consequence of ageing, warn University of Sydney experts in in a paper published in the British Medical Journal today.
ERADA Technology Alliance Ltd, pioneers of innovative, rapid diagnostic solutions for early detection of infectious diseases, have announced the imminent launch of a world first diagnostic saliva test for malaria.
› Verified 9 days ago
| Entity Name | Group Health Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710924683 PECOS PAC ID: 1759293954 Enrollment ID: O20031105000417 |
News Archive
Over 65s say they would find technology to help them take their medications helpful, but need the technology to be familiar, accessible and easy to use, according to research by Queen Mary University of London and University of Cambridge.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
A political drive, led by the UK and US, to screen older people for minor memory changes (often called mild cognitive impairment or pre-dementia) is leading to unnecessary investigation and potentially harmful treatment for what is arguably an inevitable consequence of ageing, warn University of Sydney experts in in a paper published in the British Medical Journal today.
ERADA Technology Alliance Ltd, pioneers of innovative, rapid diagnostic solutions for early detection of infectious diseases, have announced the imminent launch of a world first diagnostic saliva test for malaria.
› Verified 9 days ago
| Entity Name | Winona Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295789352 PECOS PAC ID: 8527977420 Enrollment ID: O20040106000260 |
News Archive
Over 65s say they would find technology to help them take their medications helpful, but need the technology to be familiar, accessible and easy to use, according to research by Queen Mary University of London and University of Cambridge.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
A political drive, led by the UK and US, to screen older people for minor memory changes (often called mild cognitive impairment or pre-dementia) is leading to unnecessary investigation and potentially harmful treatment for what is arguably an inevitable consequence of ageing, warn University of Sydney experts in in a paper published in the British Medical Journal today.
ERADA Technology Alliance Ltd, pioneers of innovative, rapid diagnostic solutions for early detection of infectious diseases, have announced the imminent launch of a world first diagnostic saliva test for malaria.
› Verified 9 days ago
| Entity Name | Hutchinson Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053508820 PECOS PAC ID: 0345330072 Enrollment ID: O20080312000695 |
News Archive
Over 65s say they would find technology to help them take their medications helpful, but need the technology to be familiar, accessible and easy to use, according to research by Queen Mary University of London and University of Cambridge.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
A political drive, led by the UK and US, to screen older people for minor memory changes (often called mild cognitive impairment or pre-dementia) is leading to unnecessary investigation and potentially harmful treatment for what is arguably an inevitable consequence of ageing, warn University of Sydney experts in in a paper published in the British Medical Journal today.
ERADA Technology Alliance Ltd, pioneers of innovative, rapid diagnostic solutions for early detection of infectious diseases, have announced the imminent launch of a world first diagnostic saliva test for malaria.
› Verified 9 days ago
| Entity Name | Healthpartners Rc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649470782 PECOS PAC ID: 5890126726 Enrollment ID: O20200618000378 |
News Archive
Over 65s say they would find technology to help them take their medications helpful, but need the technology to be familiar, accessible and easy to use, according to research by Queen Mary University of London and University of Cambridge.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
A political drive, led by the UK and US, to screen older people for minor memory changes (often called mild cognitive impairment or pre-dementia) is leading to unnecessary investigation and potentially harmful treatment for what is arguably an inevitable consequence of ageing, warn University of Sydney experts in in a paper published in the British Medical Journal today.
ERADA Technology Alliance Ltd, pioneers of innovative, rapid diagnostic solutions for early detection of infectious diseases, have announced the imminent launch of a world first diagnostic saliva test for malaria.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tyler John Ulbrich, MD Po Box 1309, 8170 33rd Ave S - Mail Stop 21110q, Minneapolis, MN 55425-4516 Ph: (651) 254-3456 | Dr Tyler John Ulbrich, MD 640 Jackson St, Saint Paul, MN 55101-2502 Ph: (651) 254-3456 |
News Archive
Over 65s say they would find technology to help them take their medications helpful, but need the technology to be familiar, accessible and easy to use, according to research by Queen Mary University of London and University of Cambridge.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
A political drive, led by the UK and US, to screen older people for minor memory changes (often called mild cognitive impairment or pre-dementia) is leading to unnecessary investigation and potentially harmful treatment for what is arguably an inevitable consequence of ageing, warn University of Sydney experts in in a paper published in the British Medical Journal today.
ERADA Technology Alliance Ltd, pioneers of innovative, rapid diagnostic solutions for early detection of infectious diseases, have announced the imminent launch of a world first diagnostic saliva test for malaria.
› Verified 9 days ago
Wojciech Kraszkiewicz, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-3456 Fax: 651-254-9673 | |
Nicholas Charles Boysen, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-3456 Fax: 651-254-9673 | |
Nathan M Frink, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1690 University Ave W, Suite 570, Saint Paul, MN 55104 Phone: 651-232-4800 Fax: 651-232-4899 | |
Dr. Andrew Caraganis, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 Phalen Blvd, Saint Paul, MN 55130 Phone: 651-254-7670 Fax: 651-254-7676 | |
Dr. Patrick George Manning, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-4887 Fax: 651-254-1603 | |
Anthony Williams, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-3456 Fax: 651-254-9673 | |
Samantha May Scheid, Internal Medicine Medicare: Medicare Enrolled Practice Location: 401 Phalen Blvd, Saint Paul, MN 55130 Phone: 651-254-7980 |